FMC approves Project Foundation, $560 to $635 million restructuring charges through 2027
On December 12, 2025, FMC's board approved Project Foundation, which includes exiting certain high-cost active ingredient and formulation plants and expects $175 million or more in annual run-rate savings by the end of 2027. The company expects pre-tax restructuring charges of approximately $560 to $635 million over the program's life, mostly non-cash write-offs, and separately warned of a significant non-cash goodwill and intangible impairment for 2025 unless its stock price recovers.
Key points
- Project Foundation approved December 12, 2025, targeting $175 million or more in annual run-rate savings by the end of 2027.
- Expected pre-tax restructuring charges of approximately $560 to $635 million, including $420 to $440 million in non-cash asset write-offs and/or accelerated depreciation.
- Expected cash expenditures of $140 to $195 million, including $50 to $80 million in severance.
- FMC expects a significant non-cash impairment of goodwill and intangibles in the 2025 financial statements absent a stock price recovery; the company says it will not affect cash flows.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 12, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.